Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canakinumab - Novartis

Drug Profile

Canakinumab - Novartis

Alternative Names: ACZ-885; Anti-IL-1 beta monoclonal antibody; Antibody A; Ilaris

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Charite - Universitatsmedizin Berlin; Columbia University; Novartis; Triemli hospital; University Hospital Tubingen; University Hospital Zurich
  • Class Anti-inflammatories; Antianaemics; Antigouts; Antihyperglycaemics; Antineoplastics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Juvenile rheumatoid arthritis; Inflammation; Familial Mediterranean fever; Familial autosomal dominant periodic fever
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult-onset Still's disease; Cryopyrin-associated periodic syndromes; Familial autosomal dominant periodic fever; Familial Mediterranean fever; Gouty arthritis; Juvenile rheumatoid arthritis; Peroxisomal disorders
  • Preregistration Cardiovascular disorders
  • Phase III Behcet's syndrome; Non-small cell lung cancer
  • Phase II Abdominal aortic aneurysm; Atherosclerosis; Malignant melanoma; Osteoarthritis; Peripheral arterial occlusive disorders; Pulmonary sarcoidosis; Schnitzler syndrome; Sickle cell anaemia
  • Phase I Breast cancer
  • Phase 0 Renal cell carcinoma
  • No development reported Chronic obstructive pulmonary disease
  • Discontinued Asthma; Diabetic retinopathy; Polymyalgia rheumatica; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 26 Oct 2019 Adverse events data from the phase III CONOPY-1 trial in Non-small cell lung cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
  • 27 Aug 2019 Phase-II clinical trials in Non-small cell lung cancer (Early-stage disease, Neoadjuvant therapy, Combination therapy) in France (SC) (EudraCT2018-004813-42)
  • 27 Aug 2019 Phase-II clinical trials in Non-small cell lung cancer (Monotherapy, Early-stage disease, Neoadjuvant therapy) in France (SC) (EudraCT2018-004813-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top